• SyncroPatch 384/768i

    APC with highest throughput on the market
  • SyncroPatch 384/768i

    384 cells in parallel => upgradable to 768
  • SyncroPatch 384/768i

    True HTS AND Gigaohm seals
  • SyncroPatch 384/768i

    Analysis Software even more powerful than before
  • SyncroPatch 384/768i

    Assay flexibility via high tech

2020 - Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist

icon sp96  SyncroPatch 768PE (a predecessor model of the SyncroPatch 768i instrument) publication in Medicinal Chemistry (2020)

Scott J.S., Moss T.A., Balazs A., Barlaam B., Breed J., Carbajo R.J., Chiarparin E., Davey P.R.J., Delpuech O., Fawell S., Fisher D.I., Gagrica S., Gangl E.T., Grebe T., Greenwood R.D., Hande S., Hatoum-Mokdad H., Herlihy K., Hughes S., Hunt T.A., Huynh H., Janbon S.L.M., Johnson T., Kavanagh S., Klinowska T., Lawson M., Lister A.S., Marden S., McGinnity D.F., Morrow C.J., Nissink W.M., O'Donovan D.H., Peng B., Polanski R., Stead D.S., Stokes S., Thakur K., Throner S.R., Tucker M.J., Varnes J., Wang H., Wilson D.M., Wu D., Wu Y., Yang B., Yang W.

Medicinal Chemistry (2020) doi: 10.1021/acs.jmedchem.0c01163


Herein we report the optimization of a series of tricyclic indazoles as selective estrogen receptor degraders (SERD) and antagonists for the treatment of ER+ breast cancer. Structure based design together with systematic investigation of each region of the molecular architecture led to the identification of N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine (28). This compound was demonstrated to be a highly potent SERD that showed a pharmacological profile comparable to fulvestrant in its ability to degrade ERα in both MCF-7 and CAMA-1 cell lines. A stringent control of lipophilicity ensured that 28 had favorable physicochemical and preclinical pharmacokinetic properties for oral administration. This, combined with demonstration of potent in vivo activity in mouse xenograft models, resulted in progression of this compound, also known as AZD9833, into clinical trials.

Download here

Back to Overview

SyncroPatch 384i brochure

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.